These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9927095)

  • 21. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
    Heit JA; Elliott CG; Trowbridge AA; Morrey BF; Gent M; Hirsh J
    Ann Intern Med; 2000 Jun; 132(11):853-61. PubMed ID: 10836911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.
    Lewis S; Glen J; Dawoud D; Dias S; Cobb J; Griffin X; Reed M; Sharpin C; Stansby G; Barry P
    Value Health; 2019 Aug; 22(8):953-969. PubMed ID: 31426937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.
    Eikelboom JW; Quinlan DJ; Douketis JD
    Lancet; 2001 Jul; 358(9275):9-15. PubMed ID: 11454370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery.
    Nurmohamed MT; Verhaeghe R; Haas S; Iriarte JA; Vogel G; van Rij AM; Prentice CR; ten Cate JW
    Am J Surg; 1995 Jun; 169(6):567-71. PubMed ID: 7771617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement.
    Yoo MC; Kang CS; Kim YH; Kim SK
    Int Orthop; 1997; 21(6):399-402. PubMed ID: 9498151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
    Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
    J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
    Wellington K; McClellan K; Jarvis B
    Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
    Marchetti M; Liberato NL; Ruperto N; Barosi G
    Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
    Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
    Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
    Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials.
    Zufferey P; Laporte S; Quenet S; Molliex S; Auboyer C; Decousus H; Mismetti P
    Thromb Haemost; 2003 Oct; 90(4):654-61. PubMed ID: 14515186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of low molecular weight heparin in preventing thromboembolism in trauma patients.
    Knudson MM; Morabito D; Paiement GD; Shackleford S
    J Trauma; 1996 Sep; 41(3):446-59. PubMed ID: 8810961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement.
    Heit JA
    Thromb Res; 2001 Jan; 101(1):V163-73. PubMed ID: 11342096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement.
    Kher A
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2175-83. PubMed ID: 11772313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.